- Home
- SFL vs QURE Comparison
SFL vs QURE Comparison
Compare SFL & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- QURE
- Stock Information
- Founded
- SFL 2003
- QURE 1998
- Country
- SFL Bermuda
- QURE Netherlands
- Employees
- SFL N/A
- QURE N/A
- Industry
- SFL Marine Transportation
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- QURE Health Care
- Exchange
- SFL Nasdaq
- QURE Nasdaq
- Market Cap
- SFL 1.0B
- QURE 866.3M
- IPO Year
- SFL N/A
- QURE 2007
- Fundamental
- Price
- SFL $7.37
- QURE $57.39
- Analyst Decision
- SFL Strong Buy
- QURE Strong Buy
- Analyst Count
- SFL 1
- QURE 12
- Target Price
- SFL $13.00
- QURE $69.67
- AVG Volume (30 Days)
- SFL 1.2M
- QURE 7.2M
- Earning Date
- SFL 11-05-2025
- QURE 11-04-2025
- Dividend Yield
- SFL 14.63%
- QURE N/A
- EPS Growth
- SFL N/A
- QURE N/A
- EPS
- SFL 0.26
- QURE N/A
- Revenue
- SFL $852,528,000.00
- QURE $14,337,000.00
- Revenue This Year
- SFL N/A
- QURE N/A
- Revenue Next Year
- SFL $2.63
- QURE $287.72
- P/E Ratio
- SFL $29.53
- QURE N/A
- Revenue Growth
- SFL 3.21
- QURE N/A
- 52 Week Low
- SFL $6.78
- QURE $5.03
- 52 Week High
- SFL $11.85
- QURE $60.70
- Technical
- Relative Strength Index (RSI)
- SFL 33.14
- QURE 79.87
- Support Level
- SFL $7.49
- QURE $54.03
- Resistance Level
- SFL $7.78
- QURE $57.57
- Average True Range (ATR)
- SFL 0.16
- QURE 4.53
- MACD
- SFL -0.00
- QURE 2.02
- Stochastic Oscillator
- SFL 13.37
- QURE 91.64
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.